Get started
Author

Cynthia Bedell

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
2009 · John Nemunaitis, Alex W Tong, et al. · Molecular Therapy · 265
PDF
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
2013 · Neil Senzer, John Nemunaitis, et al. · Molecular Therapy · 250
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
2011 · Neil Senzer, Minal Barve, et al. · Molecular Therapy · 198
PDF
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2013 · Geoffrey I. Shapiro, Jordi Rodon, et al. · Clinical Cancer Research · 152
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
2015 · David S. Hong, Razelle Kurzrock, et al. · Clinical Cancer Research · 70
Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
2011 · Jairo Olivares, Padmasini Kumar, et al. · Clinical Cancer Research · 55
Hereditary Inclusion Body Myopathy: Single Patient Response to Intravenous Dosing of GNE Gene Lipoplex
2011 · Gregory Nemunaitis, Chris M. Jay, et al. · Human Gene Therapy · 51
Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver
2014 · John Nemunaitis, Minal Barve, et al. · Oncology · 49
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy
2010 · Gregory Nemunaitis, Phillip B. Maples, et al. · The Journal of Gene Medicine · 30
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
2015 · Minal Barve, Zhaohui Wang, et al. · Molecular Therapy · 20
Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
2013 · John Nemunaitis, Cynthia Bedell, et al. · Journal for ImmunoTherapy of Cancer · 15
PDF
Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
2021 · Megan L. Kruse, Irene M. Kang, et al. · Oncology and Therapy · 8
PDF
Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
PDF
Supplementary Table 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
PDF
Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Table 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
PDF
Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
PDF
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
PDF
Supplementary Table 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2023 · Geoffrey I. Shapiro, Jordi Rodon, et al.
PDF
Works count: 37
Citation count: 1,163
H-index: 11
I10-index: 11
Year
Topic
Type